| Cohort I†(n = 168) | Cohort II‡ (n = 198) | Cohort III* (n = 43) |
---|---|---|---|
Age (y) | Â | Â | Â |
19-39 | 13 (8%) | 11 (6%) | 2 (5%) |
40-49 | 29 (17%) | 24 (12%) | 4 (9%) |
50-59 | 43 (26%) | 50 (25%) | 12 (28%) |
60-88 | 83 (49%) | 113 (57%) | 25 (58%) |
Not available | 0 (0%) | 0 (0%) | 0 (0%) |
Sex | Â | Â | Â |
Female | 47 (28%) | 68 (34%) | 20 (47%) |
Male | 121 (72%) | 130 (66%) | 23 (53%) |
Not available | 0 (0%) | 0 (0%) | 0 (0%) |
Tumor site | Â | Â | Â |
Oral cavity | 71 (42%) | 198 (100%) | 43 (100%) |
Not available | 97 (58%) | 0 (0%) | 0 (0%) |
Cervical lymph node status | Â | Â | Â |
pN0 | 0 (0%) | 70 (35%) | 27 (63%) |
pN1 | 0 (0%) | 98 (50%) | 16 (37%) |
Not available | 168 (100%) | 30 (15%) | 0 (0%) |
Tumor size | Â | Â | Â |
T1-T2 | 30 (18%) | 83 (42%) | 36 (84%) |
T3-T4 | 41 (24%) | 111 (56%) | 7 (16%) |
Not available | 97 (58%) | 4 (2%) | 0 (0%) |
Clinical stage | Â | Â | Â |
I/II | 71 (42%) | 61 (31%) | 25 (58%) |
III/IV | 97 (58%) | 133 (67%) | 18 (42%) |
Not available | 0 (0%) | 4 (2%) | 0 (0%) |
Differentiation | Â | Â | Â |
Well | 0 (0%) | 30 (15%) | 12 (30%) |
Moderate | 0 (0%) | 128 (65%) | 22 (51%) |
Poor | 0 (0%) | 38 (19%) | 7 (16%) |
Not available | 168 (100%) | 2 (1%) | 0 (0%) |
Tumor inflammatory infiltration | Â | Â | Â |
Minimal | 0 (0%) | 0 (0%) | 13 (30%) |
Moderate | 0 (0%) | 0 (0%) | 13 (30%) |
Strong | 0 (0%) | 0 (0%) | 16 (37%) |
Not available | 168 (100%) | 198 (100%) | 0 (0%) |
Tobacco smoking history | Â | Â | Â |
Never smoker | 15 (9%) | 46 (23%) | 18 (42%) |
Former smoker | 28 (17%) | 87 (44%) | 5 (12%) |
Current smoker | 28 (17%) | 57 (29%) | 12 (28%) |
Chewing tobacco | 0 (0%) | 0 (0%) | 1 (2%) |
Not available | 97 (58%) | 8 (4%) | 7 (16%) |
p16 | Â | Â | Â |
Negative | 97 (58%) | 0 (0%) | 35 (81%) |
Positive | 0 (0%) | 0 (0%) | 8 (19%) |
Not available | 71 (42%) | 198 (100%) | 0 (0%) |